Christopher Irobunda, MD
Interventional Cardiology · New York, NYNPI 1265516223
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novartis at 35.9% of the total. Reporting peaked in 2022 at $311 and has fallen 53.6% since, to $144 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.
Across 33 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$257
- Heartflow, Inc.$178
- Bardy Diagnostics, Inc.$67
- E.r. Squibb & Sons, L.L.C.$56
- Amgen$51
- Kiniksa Pharmaceuticals, Ltd.$26
- plus $82 from 4 others
What the payments were for
- Food & beverage$718100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $257 |
| Heartflow, Inc. | 7 | $178 |
| Bardy Diagnostics, Inc. | 2 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Amgen | 3 | $51 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Johnson & Johnson | 1 | $13 |
How this compares
$718 in reported general payments places this provider in the 5th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $90,972 |
| Metoprolol Succinate | 91 | $1,675 |
| Atorvastatin Calcium | 98 | $1,351 |
| Losartan Potassium | 91 | $1,109 |
| Rosuvastatin Calcium | 53 | $987 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 32 | $768 |
| Amlodipine Besylate | 81 | $749 |
| ClopidogrelClopidogrel Bisulfate | 22 | $647 |
| Ezetimibe | 27 | $639 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $489 |
| Carvedilol | 45 | $485 |
| Valsartan | 11 | $477 |
| Metoprolol Tartrate | 31 | $348 |
| Digoxin | 12 | $334 |
| Chlorthalidone | 22 | $312 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.